{"id":3937,"date":"2025-09-22T15:16:09","date_gmt":"2025-09-22T13:16:09","guid":{"rendered":"https:\/\/www.esptcongress.org\/?page_id=3937"},"modified":"2025-09-22T15:16:09","modified_gmt":"2025-09-22T13:16:09","slug":"hughes-dyfrig","status":"publish","type":"page","link":"https:\/\/www.esptcongress.org\/index.php\/hughes-dyfrig\/","title":{"rendered":"Hughes Dyfrig"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column width=&#8221;1\/4&#8243;]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">.shortcode-single-image-wrap.shortcode-single-image-232cb1595fd71e4de9d741974f02ca15.enable-bg-rollover .rollover i,\n.shortcode-single-image-wrap.shortcode-single-image-232cb1595fd71e4de9d741974f02ca15.enable-bg-rollover .rollover-video i {\n  background: -webkit-linear-gradient();\n  background: linear-gradient();\n}\n.shortcode-single-image-wrap.shortcode-single-image-232cb1595fd71e4de9d741974f02ca15 .rollover-icon {\n  font-size: 32px;\n  color: #ffffff;\n  min-width: 44px;\n  min-height: 44px;\n  line-height: 44px;\n  border-radius: 100px;\n  border-style: solid;\n  border-width: 0px;\n}\n.dt-icon-bg-on.shortcode-single-image-wrap.shortcode-single-image-232cb1595fd71e4de9d741974f02ca15 .rollover-icon {\n  background: rgba(255,255,255,0.3);\n  box-shadow: none;\n}<\/style><div class=\"shortcode-single-image-wrap shortcode-single-image-232cb1595fd71e4de9d741974f02ca15 alignnone  vc_custom_1758546930070 enable-bg-rollover dt-icon-bg-off\" ><div class=\"shortcode-single-image\"><div class=\"fancy-media-wrap  layzr-bg\" style=\"\"><img fetchpriority=\"high\" decoding=\"async\" class=\"preload-me lazy-load aspect\" src=\"data:image\/svg+xml,%3Csvg%20xmlns%3D&#39;http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg&#39;%20viewBox%3D&#39;0%200%20500%20500&#39;%2F%3E\" data-src=\"https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Hughes_foto-500x500.jpg\" data-srcset=\"https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Hughes_foto-500x500.jpg 500w, https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Hughes_foto-627x627.jpg 627w\" loading=\"eager\" sizes=\"(max-width: 500px) 100vw, 500px\" width=\"500\" height=\"500\"  data-dt-location=\"https:\/\/www.esptcongress.org\/index.php\/speakers\/hughes_foto\/\" style=\"--ratio: 500 \/ 500;\" alt=\"\" \/><\/div><\/div><\/div><div class=\"standard-arrow list-divider bullet-top\"><ul>\n<li>Prof Dyfrig Hughes<\/li>\n<\/ul>\n<\/div>[\/vc_column][vc_column width=&#8221;3\/4&#8243;]<div id=\"ultimate-heading-705469f30c8ad112d\" class=\"uvc-heading ult-adjust-bottom-margin ultimate-heading-705469f30c8ad112d uvc-1561 color-title accent-title-color uvc-heading-default-font-sizes\" data-hspacer=\"no_spacer\"  data-halign=\"left\" style=\"text-align:left\"><div class=\"uvc-heading-spacer no_spacer\" style=\"top\"><\/div><div class=\"uvc-main-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-705469f30c8ad112d h2'  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}' ><h2 style=\"--font-weight:theme;\">CV<\/h2><\/div><div class=\"uvc-sub-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-705469f30c8ad112d .uvc-sub-heading '  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}'  style=\"font-weight:normal;\">Dyfrig Hughes is professor of pharmacoeconomics at Bangor University, Wales, where he directs the Pharmaceutical Economics, Policy and Prescribing Research group. He has published extensively on research concerning the safe, effective and efficient use of medicines. This has included a series of economic evaluations of pharmacogenomic tests relating to treatment with abacavir, allopurinol, carbamazepine, clopidogrel, fluoropyrimidines, irinotecan, and warfarin; as well as multi-gene panels. Dyfrig is part of the UK\u2019s Pharmacogenomics Centre of Excellence for Regulatory Science and Innovation; is vice-chair of the All Wales Medicines Strategy Group (which is the statutory body that advises the Welsh Minister on strategic developments in medicines management and prescribing); chairs the National Pharmacogenomics Group for the National Health Service in Wales (responsible for the implementation of pharmacogenomics); and co-chairs NHS England\u2019s Pharmacogenomics Test Evaluation Working Group (advising on the National Genomics Test Directory).<\/div><\/div><div id=\"ultimate-heading-344169f30c8ad1177\" class=\"uvc-heading ult-adjust-bottom-margin ultimate-heading-344169f30c8ad1177 uvc-8224 color-title accent-title-color uvc-heading-default-font-sizes\" data-hspacer=\"no_spacer\"  data-halign=\"left\" style=\"text-align:left\"><div class=\"uvc-heading-spacer no_spacer\" style=\"top\"><\/div><div class=\"uvc-main-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-344169f30c8ad1177 h2'  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}' ><h2 style=\"--font-weight:theme;margin-top:50px;\">ABSTRACT<\/h2><\/div><div class=\"uvc-sub-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-344169f30c8ad1177 .uvc-sub-heading '  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}'  style=\"font-weight:normal;\">Pharmacogenetic tests are being promoted and used increasingly to prevent adverse drug reactions and improve the efficacy of treatments. However, payers of healthcare often require evidence on the cost-effectiveness of testing to justify and support widespread clinical implementation. Cost-effectiveness does not imply cost-saving\u2014indeed, economic evaluations have dispelled a perception that precision medicine, achieved through pharmacogenetic testing, reduces healthcare costs. For many tests aimed at preventing adverse drug reactions, cost-effectiveness analyses predict modest improvements in health benefits and increases in total costs. While there are many uncertainties in estimating the value of testing, factors that influence cost-effectiveness include the rarity of the outcome, the effectiveness and safety of alternative treatments, and the scope and perspective of analysis. Drawing from a range of examples, this presentation will illustrate how cost-effectiveness estimates are sensitive to such factors, describe the analytical challenges of assessing the value of pharmacogenomic panel testing, and discuss whether and how broader societal impacts should be considered when evaluating pharmacogenomic testing services.<\/div><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column width=&#8221;1\/4&#8243;][\/vc_column][vc_column width=&#8221;3\/4&#8243;][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3937","page","type-page","status-publish","hentry","description-off"],"_links":{"self":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/comments?post=3937"}],"version-history":[{"count":2,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3937\/revisions"}],"predecessor-version":[{"id":3939,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3937\/revisions\/3939"}],"wp:attachment":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/media?parent=3937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}